 Dynavax Technologies Corporation NASDAQ: DVAX has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B, the Hepatitis B vaccine in Germany, with an expected launch in the fourth quarter of 2021. Financial terms were not disclosed. 